SYNERGY MONORAIL Everolimus-Eluting Platinum Chromium Coronary Stent System 몬테네그로 - 크로아티아어 - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

synergy monorail everolimus-eluting platinum chromium coronary stent system

"farmont m.p." d.o.o. za proizvodnju, promet i usluge, export-import danilovgrad - neaktivna implantabilna medicinska sredstva

Promus ELITE MONORAIL Everolimus-Eluting Platinum Chromium Coronary Stent System 몬테네그로 - 크로아티아어 - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

promus elite monorail everolimus-eluting platinum chromium coronary stent system

"farmont m.p." d.o.o. za proizvodnju, promet i usluge, export-import danilovgrad - medicinska sredstva za jednokratnu upotrebu

Imbruvica 유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

VAXCEL CHRONIC DIALYSS KATETER 크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

vaxcel chronic dialyss kateter

boston medical d.o.o., zagreb - trajni kateter za dijalizu kroničnih nefroloških bolesnika

Vafseo 유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

vafseo

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - antianemijski pripravci - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

Pegasys 유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

pegasys

pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - Иммуностимуляторы, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 i 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. s poštovanjem za rješavanje započeti liječenje u pedijatrijska bolesnika vidi 4. 2, 4. 4 i 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 i 5. virus hepatitisa c (hcv) genotip određene aktivnosti, vidi 4. 2 i 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. pri rješavanju početak liječenja u dječjoj dobi, važno je uzeti u obzir inhibicija rasta, izazvana kombinovanu terapiju. Обратимость inhibicije rasta povjerenja. odluka mora biti donesena na individualnoj osnovi (vidi odjeljak 4.